MedTrace Logo

MIRODERM H2H DFU Study

NCT03232333 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 53

Last updated 2019-10-22

Study results available
· View outcomes & findings →

Summary

This study will assess the ability of MIRODERM to heal difficult diabetic foot ulcers within 12 weeks of treatment.

Conditions

  • Diabetic Foot Ulcer

Interventions

DEVICE

Biologic wound graft

Diabetic foot ulcer will be treated by grafting with MIRODERM Biologic Wound Matrix

Sponsors & Collaborators

  • Miromatrix Medical Inc.

    lead INDUSTRY

Principal Investigators

  • Robert Fridman, DPM · Foot Associates of New York

  • M Mason Macenski, PhD · Miromatrix

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-21
Primary Completion
2018-09-20
Completion
2018-09-20
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03232333 on ClinicalTrials.gov